GSK3B and neoplasm: However, in malignancies where GSK3β plays a tumor suppressor role but is inactivated by oncogenic pathways through S9-phosphorylation [22–27], GSK3β-targeted strategies could rely on the suppression of the inhibitory pathways [32, 59–61].